References
- Richman DM, Tirumani SH, Hornick JL, et al. Beyond gastric adenocarcinoma: multimodality assessment of common and uncommon gastric neoplasms. Abdominal Radiology. 2017;42(1):124–140. doi:10.1007/s00261-016-0901-x
- Chunxiao W, Kai G, Yangming G, et al. Analysis of the onset and death of colorectal cancer in China in 2015. Chin J Cancer. 2020;30(4):241–245.
- Yachong J, Xuchu Z, Jiajie W, Dezhi K, Bin Z. Clinical diagnostic value of combined serum tumor marker measurement for nodal recurrence and metastasis detection. Mark Immun Clin. 2021;28(07):1106–1109.
- Hao Y, Jiaming L, Kun Z, Xin Z, Kun H. The clinical value of postoperative serum CEA with CA19-9-9, YKL-40, CRP and IL-6 in predicting recurrence and survival of colorectal cancer. Mod Med. 2022;50(09):1143–1150.
- Konishi T, Shimada Y, Hsu M. et al.Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 2018;4(3):309–315. doi:10.1001/jamaoncol.2017.4420
- Sjin JK, Kim HC, Lee WY, et al. High preoperative serum CA 19-9 levels can predict poor oncologic outcomes in colorectal cancer patients on propensity score analysis. Ann Surg Treat Res. 2019;96(3):107–115. doi:10.4174/astr.2019.96.3.107
- Song Z, Yuan HL, Yeqiang Q, Yunfei C, Xiaoxia Z, Huan Z. Diagnostic value of the combined detection of different serum tumor markers in digestive tract malignancies. Pharmaceut Oncol. 2014;4(04):282–285.
- Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–648. doi:10.1016/S0140-6736(20)31288-5
- Wang H. Significance of combined detection of tumor markers in the diagnosis of cancer. J Basic Clin Oncol. 2013;26(4):357–358.
- Juan Z, Zhenghao Z, Nannan P, Jialin Z, Jianhua Q. Progress in studying the expression and mechanism of Tim-3 in malignant tumors. J Pract Med. 2017;33(21):3667–3670.
- Xu B, Yuan L, Gao Q, et al. Circulating and tumor⁃infiltrating Tim- 3 in patients with colorectal cancer. Oncotarget. 2015;6(24):20592–20603. doi:10.18632/oncotarget.4112
- Zhou E, Huang Q, Wang J, et al. Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int J Clin Exp Pathol. 2015;8(7):8018–8027.
- Huang YH, Zhu C, Kondo Y, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386–390. doi:10.1038/nature13848
- Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res. 2011;71(21):6567–6571. doi:10.1158/0008-5472.CAN-11-1487
- Chen M, Wang L, Wang Y, et al. Soluble Tim3 detection by time-resolved fluorescence immunoassay and its application in membranous nephropathy. J Clin Lab Anal. 2020;34(6):23248.
- Difu P, Lamei G, Anming F, Kean Z. Report of 60 cases of reoperation of colorectal cancer. Chin J General Surg. 2007;09:849–851.
- The National Health Commission, PRC. China code for diagnosis and treatment of colorectal cancer (2020 edition). Chin J Surg. 2020;58(8):561–585.
- Zhang Y, Cai P, Liang T, et al. TIM-3 is a potential prognostic marker for patients with solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(19):31705–31713. doi:10.18632/oncotarget.15954
- Mokhles S, Macbeth F, Farewell V, et al. Meta- analysis of colorectal cancer follow-up after potentially curative resection. Br J Surg. 2016;103(10):1259–1268. doi:10.1002/bjs.10233
- You YN, Hardiman KM, Bafford A, et al. The American society of colon and rectal surgeons clinical practice guidelines for the management of rectal cancer. Dis Colon Rectum. 2020;63(9):1191–1222. doi:10.1097/DCR.0000000000001762
- Lech G, Slotwinski R, Slodkowski M, et al. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastro Enterol. 2016;22(5):1745–1755. doi:10.3748/wjg.v22.i5.1745
- Kotzev A. CA19-9 in follow-up of patients with colorectal cancer: Should it stay or should it go. J Buon. 2019;24(3):1310–1311.
- Papagrigoriadis S. Follow-up of patients with colorectal cancer: the evidence is in favour but we are still in need of a protocol. Int J Surg. 2007;5(2):120–128. doi:10.1016/j.ijsu.2006.04.004
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.29210
- Huang YK, Yu JC, Kang WM, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic ic review and meta-analysis. PLoS One. 2015;10(11):14208.